Skip to main
CRMD
CRMD logo

CorMedix (CRMD) Stock Forecast & Price Target

CorMedix (CRMD) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cormedix Inc. demonstrates a strong positive outlook as it has increased its full-year 2025 pro forma net revenue guidance to a range of $390–$410 million, attributed to robust adoption of its product DefenCath and early contributions from the Melinta portfolio. The fourth-quarter net revenue is projected to be between $115 million and $135 million, indicating sustained momentum as the year concludes. Additionally, CorMedix's better-than-expected performance in the third quarter, with net revenue reaching $104.3 million due to higher utilization of DefenCath, further supports the company's strong commercial execution narrative.

Bears say

Cormedix Inc. faces significant challenges as the price of its product, DefenCath, is expected to drop notably upon the second phase of the Transitional Drug Add-On Payment Adjustment (TDAPA) in July 2026, which may undermine revenue projections. The potential failure of DefenCath to capture market share against generic competitors, such as Heparin, further complicates the company's sales outlook, especially in the catheter lock solution segment. While there are identified tailwinds for the company over the next couple of years, the looming uncertainties surrounding TDAPA pricing and competitive pressures create a negative outlook for Cormedix's financial future.

CorMedix (CRMD) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CorMedix (CRMD) Forecast

Analysts have given CorMedix (CRMD) a Buy based on their latest research and market trends.

According to 6 analysts, CorMedix (CRMD) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CorMedix (CRMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.